Scarica l'app Stockscreener
20.14
4.87%
-1.03
Dopo l'orario di chiusura:
20.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
A better buy-in window may exist right now for Celldex Therapeutics Inc (CLDX) - SETE News
Celldex Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Celldex’s CDX-622 shows promise for inflammatory disorders - BioWorld Online
Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
CLDXCelldex Therapeutics Inc Latest Stock News & Market Updates - StockTitan
H.C. WAINWRIGHT MAINTAINS BUY RATING, $80 TARGET ON CELLDEX STOCK - Investing.com UK
Celldex Therapeutics (NASDAQ:CLDX) Price Target Lowered to $36.00 at The Goldman Sachs Group - Defense World
UBS Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - MSN
Celldex Therapeutics Reports Positive Preclinical Data For Inflammation Drug - Nasdaq
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - The Manila Times
Can Celldex's Dual-Mechanism CDX-622 Transform Inflammatory Disease Treatment? - StockTitan
Celldex Therapeutics’ (CLDX) Buy Rating Reiterated at HC Wainwright - Defense World
Celldex announces data from Phase 2 barzolvolimab studies - MSN
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - The Manila Times
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients ... - Enid News & Eagle
Can Celldex's Urticaria Treatment Transform Patient Lives? Phase 2 Data Shows 95% Quality of Life Improvement - StockTitan
Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from HC Wainwright - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics - Benzinga
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Celldex: Q4 Earnings Snapshot - The Washington Post
Celldex Therapeutics Advances Pipeline Amid Financial Challenges - TipRanks
Celldex reports Q4 EPS (71c), consensus (71c) - TipRanks
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Celldex: Q4 Earnings Snapshot -February 27, 2025 at 04:33 pm EST - Marketscreener.com
Celldex Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics, Inc. SEC 10-K Report - TradingView
Can Celldex's $725M War Chest and Promising Clinical Data Deliver Returns for Investors? - StockTitan
Celldex stock touches 52-week low at $20.86 amid market challenges - Investing.com India
Celldex Therapeutics Inc (CLDX) Recovers 7.41% From Low: Are We There Yet? - Stocks Register
Celldex Therapeutics (CLDX) Projected to Post Earnings on Monday - Defense World
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - MSN
Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX-622 - Wiley Online Library
Chronic Spontaneous Urticaria Market to Register - GlobeNewswire
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Celldex Therapeutics (CLDX) Expected to Announce Earnings on Monday - MarketBeat
What is Leerink Partnrs' Forecast for CLDX Q1 Earnings? - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $60.22 Average Price Target from Analysts - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by TSP Capital Management Group LLC - MarketBeat
Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price at $60.22 - Armenian Reporter
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
How InvestingPro spotted Celldex's overvaluation before 46% decline By Investing.com - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Now Covered by UBS Group - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Hits New 12-Month LowHere's Why - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from Analysts at UBS Group - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Q1 Earnings Forecast for CLDX Issued By Leerink Partnrs - Defense World
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):